

SARS CoV2 Antibody Change



Clayton Wilburn, MD
 Medical Director
 Clinical Chemistry
 Phone: 847-9657

On 10/27/21, the UVMHC Laboratory will be changing the Mayo antibody test reflexed from Pathology Approval for COVID-19 IgG Ab, LAB14475. The SARS CoV2 **Nucleocapsid** Total Ab, S will replace the SARS CoV2 **Spike** Antibody, Semi-Quantitative, S. This change is in-line with the approved clinical use for COVID-19 serology, testing for exposure to natural infection in individuals being evaluated for MIS-C or “Long COVID” who do not have a prior positive PCR test for COVID-19. By measuring antibodies developed to the COVID-19 Nucleocapsid, we are eliminating the interference from the current vaccines that induce antibodies to the COVID-19 spike protein in evaluating past natural infection/exposure.

Orderable Name	Epic Code	Atlas Code	Mayo ID	LOINC
Pathology Approval for COVID IgG Ab	LAB14475	LAB14475	N/A	N/A
Newly Defined Mayo Test (Lab Use Only)	Epic Code	Atlas Code	Mayo ID	LOINC
SARS-CoV-2 Nucleocapsid Total Ab, S.	LAB17155	N/A	COVTA	94762-2
Result Components	Epic Code	Atlas Code	Mayo ID	LOINC
SARS CoV 2 Nucleocapsid Total Ab, S	12301018363	N/A	COVTI	94762-2
Patient's Race	12301013084	N/A	SRACE	72826-1
Patient's Ethnicity	12301013085	N/A	SETHN	69490-1
Currently Defined Mayo Test (Lab Use Only)	Epic Code	Atlas Code	Mayo ID	LOINC
SARS-CoV-2 Spike Ab, Semi-Quant, S.	LAB15556	N/A	COVSQ	94769-7

The UVMHC laboratory still does not support testing for COVID-19 antibodies to assess vaccine response at this time. The reasons behind this are as follows: The current assays are semi-quantitative or qualitative with no set value being stated as indicative of immune status. The CDC and FDA currently do not support SARS-COV-2 ab testing post-vaccination to assess immunity ([CDC COVID-19 Serology and Vaccination Guidance](#)) and ([FDA COVID-19 Serology and Vaccination Guidance](#)) and there is no guidance on how one would modify an existing vaccination schedule or re-dose should a negative result be obtained.

Further guidance from the CDC for immunocompromised patients can be found here <https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html#underlying-conditions>.

Should the guidance change on post-vaccination serology testing, the UVMHC will be updating our internal guidelines and testing strategy.

If you have any questions or concerns about these changes, then please reach out to the Medical Director of Clinical Chemistry (clayton.wilburn@uvmhealth.org).

PATHOLOGY & LABORATORY MEDICINE

111 Colchester Avenue | Mail Stop: 233MP1 | Burlington, Vermont 05401

PHONE LABORATORY CUSTOMER SERVICE

(802) 847-5121 | (800) 991-2799

